Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer
H Zhou, L Zhu, J Song, G Wang, P Li, W Li, P Luo… - Molecular cancer, 2022 - Springer
Colorectal cancer (CRC) is one of the most common cancers worldwide and a leading
cause of carcinogenic death. To date, surgical resection is regarded as the gold standard by …
cause of carcinogenic death. To date, surgical resection is regarded as the gold standard by …
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
D Kotani, E Oki, Y Nakamura, H Yukami, S Mishima… - Nature medicine, 2023 - nature.com
Despite standard-of-care treatment, more than 30% of patients with resectable colorectal
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …
cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer
AR Parikh, EE Van Seventer, G Siravegna… - Clinical Cancer …, 2021 - AACR
Purpose: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery
can identify patients with minimal residual disease (MRD) who will ultimately recur. Most …
can identify patients with minimal residual disease (MRD) who will ultimately recur. Most …
The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of colon cancer
METHODS This guideline is based on the previous colon cancer parameter published in
2017. 10 Compared with 2017, this guideline has 11 new, 10 updated, and 2 excluded …
2017. 10 Compared with 2017, this guideline has 11 new, 10 updated, and 2 excluded …
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
S Pant, ZA Wainberg, CD Weekes, M Furqan… - Nature medicine, 2024 - nature.com
Pancreatic and colorectal cancers are often KRAS mutated and are incurable when tumor
DNA or protein persists or recurs after curative intent therapy. Cancer vaccine ELI-002 2P …
DNA or protein persists or recurs after curative intent therapy. Cancer vaccine ELI-002 2P …
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …
Using circulating tumor DNA in colorectal cancer: current and evolving practices
There exists a tremendous opportunity in identifying and determining the appropriate
predictive and prognostic biomarker (s) for risk stratification of patients with colorectal …
predictive and prognostic biomarker (s) for risk stratification of patients with colorectal …
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer
One of the great challenges in therapeutic oncology is determining who might achieve
survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA …
survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA …